GPP
RVLP

Great Point Partners’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Great Point Partners’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-926,933
Closed -$3.52M – 43
2019
Q2 		$3.52M Sell
926,933
-573,067
-38% -$1.91M 0.39% 26
2019
Q1 		$5.4M Hold
1,500,000
– – 0.53% 30
2018
Q4 		$11.6M Buy
+1,500,000
New +$12M 1.47% 22

Other funds holding RVLP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Great Point Partners's RVLP Position: Q3 2019 in Review

Great Point Partners sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2019, closing a stake of 926,933 shares — an estimated $3.52M sold.

Great Point Partners first reported a position in RVLP in Q4 2018 and held it in 3 quarters. The position peaked at $11.6M in Q4 2018. 40 funds tracked by Wall St. Rank hold RVLP as of Q3 2019.

  • Great Point Partners reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • Great Point Partners sold 926,933 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2019, an estimated $3.52M.
  • Great Point Partners first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 3 quarters.
  • Great Point Partners's RVL Pharmaceuticals plc Ordinary Shares position peaked at $11.6M in Q4 2018.
  • 40 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2019.

Based on Great Point Partners's 13F filing for Q3 2019, filed 15 Nov 2019.